Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same
AssigneeShin Poong Pharmaceutical Co., Ltd.
InventorsJei Man Ryu, Dong Won Lee, Kang Hyeok Lee, Jin Hun Park, Geum Sil Cho, Ki Sung Lee, Jin Ho Chung, Woo Ile Park, Jae Young Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel compound having an effect of inhibiting platelet aggregation and a salt thereof and, more specifically, to: a novel platelet aggregation inhibitor specifically inhibiting shear stress-induced platelet aggregation; a pharmaceutical composition containing the same as an active ingredient; and a preparation method therefor.
Claims8
A compound represented by the following Formula (I) or (II), or a pharmaceutically acceptable salt or stereoisomer thereof:
- wherein,
- R1 is hydroxy or C1-C10 alkoxy;
- X is N or O;
- R2 is —(CH2)p-5- to 12-membered heterocycle-(CH2)p—C6-C12 aryl, 5- to 12-membered heterocycle, —(CH2)p—NHC(═O)—C6-C12 aryl, —CHR4R5, 5- to 12-membered heteroaryl, C6-C12 aryl, —C6-C12 aryl-O-5- to 12-membered heteroaryl, or —(CH2)p-5- to 12-membered heteroaryl, provided that when R2 is (CH2)p-5- to 12-membered heteroaryl, the heteroaryl is not pyrazine, pyridine or indole, and when R2 is 5- to 12-membered heteroaryl, the heteroaryl is not benzothiazole;
- wherein p is an integer of 1 to 10;
- R4 and R5 are each independently C1-C6 alkoxycarbonyl or —CH2-5- to 12-membered heteroaryl;
- wherein said heterocycle and heteroaryl may contain 1 to 3 heteroatoms selected from N, O and S;
- said aryl can be substituted with 1 to 4 substituents selected from the group consisting of aminocarbonyl, nitro, nitrile, C1-C6 alkylaminocarbonyl, and hydroxy-C1-C6 alkyl and said heterocycle and heteroaryl is substituted with 1 to 4 substituents selected from the group consisting of halogen, oxo, aminocarbonyl, nitro, C1-C6 alkoxy, nitrile, C1-C6 alkylamino carbonyl, hydroxyl, and hydroxyl-C1-C6 alkyl;
- R3 is hydrogen;
- when X is O, R3 does not exist;
- or
- when X is N, X taken together with R2 and R3 may form a 5- to 12-membered heterocycle containing 1 to 3 heteroatoms selected from O, N and S;
- wherein said heterocycle can be substituted with C6-C12 aryl;
- a 6- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N and S, which is unsubstituted or substituted with halogen;
- or —O—CHR6R7;
- and wherein R6 and R7 are each independently C6-C12 aryl or a 6- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S, both of which are unsubstituted or substituted with halogen,
- provided that when X is N, X taken together with R2 and R3 forms a 6-membered heterocycle, said heterocycle is substituted with C6-C12 aryl;
- a 6- to 12-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N, and S, which is unsubstituted or substituted with halogen or —OCHR6R7.
A compound which is selected from the following group:
- (6,7-Dihydrothieno[3,2-c]pyridin-5(4H)-yl)(3,4-dihydroxyphenyl)methanone;
- (3,4-Dihydroxyphenyl)(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)methanone;
- N-((4-(4-Fluorobenzyl)morpholin-2-yl)methyl)-3,4-dihydroxybenzamide;
- 3,4-Dihydroxy-N-(2-oxotetrahydrothiophen-3-yl)benzamide;
- N, N′-(Nonan-1,9-diyl)bis(3,4-dihydroxybenzamide);
- (4-((4-Chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)(3,4-dihydroxyphenyl)methanone;
- (S)-(4-((4-Chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)(3,4-dihydroxyphenyl)methanone;
- (S)-Methyl-2-(3,4-dihydroxybenzamido)-3-(1H-indol-3-yl)propanoate;
- 4-(3,4-Dihydroxybenzamido)-1-methyl-3-propyl-1H-pyrazole-5-carboxamide;
- 2-Methyl-4-oxo-4H-pyran-3-yl 3,4-dihydroxybenzoate;
- (3,4-Dihydroxyphenyl)(4-phenylpiperazin-1-yl)methanone;
- (6,7-Dihydrothieno[3,2-c]pyridin-5(4H)-yl)(4-hydroxy-3-methoxyphenyl)methanone;
- 2-Ethyl-4-oxo-4H-pyran-3-yl 4-hydroxy-3-methoxybenzoate;
- 2-Methyl-4-oxo-4H-pyran-3-yl 4-hydroxy-3-methoxybenzoate;
- 4-Hydroxy-3-methoxy-N-(4-methoxy-2-nitrophenyl)benzamide;
- 4-(4-(4-Hydroxy-3-methoxybenzamido)phenoxy)-N-methylpicolinamide;
- 4-((4-Chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)(4-hydroxy-3-methoxyphenyl)methanone;
- 4-Hydroxy-N-((3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl)methyl)-3-methoxybenzamide;
- (6,7-Dihydrothieno[3,2-c]pyridin-5(4H)-yl)(2,5-dihydroxyphenyl)methanone;
- (4-((4-Chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)(2,5-dihydroxyphenyl)methanone;
- N-((4-(4-Fluorobenzyl)morpholin-2-yl)methyl)-2,5-dihydroxybenzamide;
- (2,5-Dihydroxyphenyl)(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)methanone;
- N-(3,4-Dimethoxyphenethyl)-2,5-dihydroxybenzamide;
- 2,5-Dihydroxy-N-(2-(thiophen-2-yl)ethyl)benzamide;
- and
- 2,5-Dihydroxy-N-(2-oxotetrahydrothiophen-3-yl)benzamide,
- or a pharmaceutically acceptable salt or stereoisomer thereof.
Dependencies are inferred from the claim text.